Table 4.

Adverse events, infectious diseases, and other disorders reported during VDZ therapy.

Adverse Event	UC (n = 147)	CD (n = 127)	Total
Infusion reaction and hypersensitivity	2 (1.4)	0 (0)	2 (0.7)
HBV reactivation	0 (0)	1 (0.8)	1 (0.4)
HCV reactivation	0 (0)	0 (0)	0 (0)
TB reactivation	0 (0)	0 (0)	0 (0)
Upper respiratory tract infection	0 (0)	1 (0.8)	1 (0.4)
Gastrointestinal tract infection	0 (0)	2 (1.6)	2 (0.7)
Others
Hair loss	0 (0)	1 (0.8)	1 (0.4)
Headache	1 (0.7)	0 (0)	1 (0.4)
SAE
Pneumonia	0 (0)	0 (0)	0 (0)
Opportunistic infection	0 (0)	1 (0.8)	1 (0.4)
Intractable infection	0 (0)	1 (0.8)	1 (0.4)
Intra-abdominal abscess	0 (0)	1 (0.8)	1 (0.4)
Intestinal perforation	1 (0.7)	0 (0)	1 (0.4)
Malignancy	0 (0)	0 (0)	0 (0)
Mortality	0 (0)	0 (0)	0 (0)

Values are n (%).

Abbreviations: CD, Crohn’s disease; HBV, hepatitis B virus; HCV, hepatitis C virus; SAE, serious adverse event; TB, tuberculosis; UC, ulcerative colitis; VDZ, vedolizumab.